Cansino Biologics, Inc. Class ASSE: 688185

Announcement on Obtaining Notice of Approval for Drug Clinical Trial for 24-Valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197, TT)

· Issued by Cansino Biologics, Inc. Class A via Shanghai Stock Exchange
Announcement on Obtaining Notice of Approval for Drug Clinical Trial for 24-Valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197, TT)

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

Company analysis